Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...
Special edition of Globe Magazine honors the best employers in Massachusetts BOSTON, MA, UNITED STATES, January 14, ...